Detemir potential applications in the treatment of diabetes during pregnancy: proven benefits and perspectives

In recent years there is notable growing prevalence of gestational and overt diabetes in pregnant women while rate of obstetric complications, neonatal morbidity, perinatal mortality in women with diabetes is maintained at the high level as compared with common population. Furhermore no doubt that f...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lyudmila A. Ruyatkina, Maksim Y. Sorokin
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2016
Materias:	diabetes mellitus pregnancy insulin therapy detemir glycemic variability fetal programming Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/57a08367b1984eb0ad169b8f3b5b3762
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:57a08367b1984eb0ad169b8f3b5b3762
record_format	dspace
spelling	oai:doaj.org-article:57a08367b1984eb0ad169b8f3b5b37622021-11-14T09:00:20ZDetemir potential applications in the treatment of diabetes during pregnancy: proven benefits and perspectives2072-03512072-037810.14341/DM2004150-55https://doaj.org/article/57a08367b1984eb0ad169b8f3b5b37622016-05-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7558https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378In recent years there is notable growing prevalence of gestational and overt diabetes in pregnant women while rate of obstetric complications, neonatal morbidity, perinatal mortality in women with diabetes is maintained at the high level as compared with common population. Furhermore no doubt that fetal programming and genetic factors induce the formation of various longterm complications in infants of diabetic mothers. There is a strong evidence that the risk of obstetric complications can be reduced by achieving adequate glycemic control, which is frequently still an elusive goal. Improved pharmacokinetic and pharmacodynamic profiles of the insulin analogs (including minimal action variability) allow to achieve a better glycemic control with lower risk of hypoglycemias compared to human insulin. The clinical benefits of detemir have been confirmed in clinical trials in pregnant women with diabetes. Detemir is the only long-acting insulin analog that has been evaluated in prospective studies in pregnant women and proved a satisfactory safety profile and the ability to achieve a lower level of fasting glycemia and advanced maturity of the fetus at delivery.Lyudmila A. RuyatkinaMaksim Y. SorokinEndocrinology Research Centrearticlediabetes mellituspregnancyinsulin therapydetemirglycemic variabilityfetal programmingNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 19, Iss 2, Pp 171-178 (2016)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus pregnancy insulin therapy detemir glycemic variability fetal programming Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus pregnancy insulin therapy detemir glycemic variability fetal programming Nutritional diseases. Deficiency diseases RC620-627 Lyudmila A. Ruyatkina Maksim Y. Sorokin Detemir potential applications in the treatment of diabetes during pregnancy: proven benefits and perspectives
description	In recent years there is notable growing prevalence of gestational and overt diabetes in pregnant women while rate of obstetric complications, neonatal morbidity, perinatal mortality in women with diabetes is maintained at the high level as compared with common population. Furhermore no doubt that fetal programming and genetic factors induce the formation of various longterm complications in infants of diabetic mothers. There is a strong evidence that the risk of obstetric complications can be reduced by achieving adequate glycemic control, which is frequently still an elusive goal. Improved pharmacokinetic and pharmacodynamic profiles of the insulin analogs (including minimal action variability) allow to achieve a better glycemic control with lower risk of hypoglycemias compared to human insulin. The clinical benefits of detemir have been confirmed in clinical trials in pregnant women with diabetes. Detemir is the only long-acting insulin analog that has been evaluated in prospective studies in pregnant women and proved a satisfactory safety profile and the ability to achieve a lower level of fasting glycemia and advanced maturity of the fetus at delivery.
format	article
author	Lyudmila A. Ruyatkina Maksim Y. Sorokin
author_facet	Lyudmila A. Ruyatkina Maksim Y. Sorokin
author_sort	Lyudmila A. Ruyatkina
title	Detemir potential applications in the treatment of diabetes during pregnancy: proven benefits and perspectives
title_short	Detemir potential applications in the treatment of diabetes during pregnancy: proven benefits and perspectives
title_full	Detemir potential applications in the treatment of diabetes during pregnancy: proven benefits and perspectives
title_fullStr	Detemir potential applications in the treatment of diabetes during pregnancy: proven benefits and perspectives
title_full_unstemmed	Detemir potential applications in the treatment of diabetes during pregnancy: proven benefits and perspectives
title_sort	detemir potential applications in the treatment of diabetes during pregnancy: proven benefits and perspectives
publisher	Endocrinology Research Centre
publishDate	2016
url	https://doaj.org/article/57a08367b1984eb0ad169b8f3b5b3762
work_keys_str_mv	AT lyudmilaaruyatkina detemirpotentialapplicationsinthetreatmentofdiabetesduringpregnancyprovenbenefitsandperspectives AT maksimysorokin detemirpotentialapplicationsinthetreatmentofdiabetesduringpregnancyprovenbenefitsandperspectives
_version_	1718429528445943808

Detemir potential applications in the treatment of diabetes during pregnancy: proven benefits and perspectives

Ejemplares similares